Success Metrics

Clinical Success Rate
62.5%

Based on 5 completed trials

Completion Rate
63%(5/8)
Active Trials
0(0%)
Results Posted
100%(5 trials)
Terminated
3(33%)

Phase Distribution

Ph phase_2
2
22%
Ph phase_4
5
56%
Ph phase_3
1
11%

Phase Distribution

0

Early Stage

2

Mid Stage

6

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
2(25.0%)
Phase 3Large-scale testing
1(12.5%)
Phase 4Post-market surveillance
5(62.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

55.6%

5 of 9 finished

Non-Completion Rate

44.4%

4 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(5)
Terminated(4)

Detailed Status

Completed5
Terminated3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
62.5%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (25.0%)
Phase 31 (12.5%)
Phase 45 (62.5%)

Trials by Status

terminated333%
withdrawn111%
completed556%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_2

Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection

NCT05304715
completedphase_2

ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI

NCT03829475
terminatedphase_4

Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).

NCT04626947
completedphase_3

Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)

NCT03182907
terminatedphase_4

Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.

NCT03756454
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05304715Phase 2

Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection

Completed
NCT03829475Phase 2

ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI

Completed
NCT04626947Phase 4

Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).

Terminated
NCT03182907Phase 3

Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)

Completed
NCT03756454Phase 4

Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.

Terminated
NCT05077085Phase 4

Bezlotoxumab Versus FMT for Multiple Recurrent CDI

Withdrawn
NCT04317963

Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection

Completed
NCT03937999Phase 4

Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.

Terminated
NCT03880539Phase 4

Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9